In the previous classification, hemangioma was a generic term for a class of diseases that contained multiple lesion forms, and the classification and nomenclature were not very precise. In the latest national symposium, an updated classification and nomenclature was proposed for this class of diseases, which is divided into two categories: hemangioma and vascular malformation, of which vascular malformation contains five subtypes. Hemangiomas are most often seen at birth or shortly after birth. They originate from residual embryonic angiogenic cells and are believed in Chinese medicine to be related to fetal heat and blood heat, caused by dysfunction of the heart and liver. Hemangiomas occurring in the maxillofacial region are mostly found in the skin and subcutaneous tissues of the face and neck, and rarely in the oral mucosa. The course of the disease can be divided into three phases: the proliferative phase, the receding phase and the complete receding phase. The proliferative phase usually accompanies the first growth period of infants, i.e., after 4 weeks of life, and can lead to facial deformities and affect motor functions such as eye closure and mouth opening. It usually enters the resting phase after 1 year of age, with complete regression in about 50-60% of patients within 5 years and in 75% within 7 years. Regression is complete at approximately 10-12 years of age. After the regression of large hemangiomas, there may be local sequelae such as hyperpigmentation, scarring, and skin atrophy and sagging. The treatment of hemangioma in infants and children needs to be judged according to the age, weight and physical condition of the child. The current treatment methods are mainly oral insulin and local injection of sclerosing agent, both of which can receive good results. It is noteworthy that the medicine of “Tipsan”, which is used to treat heart disease in adults, also has the effect of promoting the regression of infant and child hemangioma, and must be taken under the guidance of professional doctors.